Key result
PTCA alleviates symptoms in stable angina, has similar mortality to bypass surgery in multivessel disease, and reduces recurrent ischemic events compared to thrombolysis in acute myocardial infarction.
Why the study?
Does percutaneous transluminal coronary angioplasty (PTCA) improve clinical outcomes across different presentations of coronary artery disease compared to medical therapy, bypass surgery, or thrombolysis?
Population
Patients with coronary artery disease, including those with stable angina, multivessel disease, unstable…
Comparison
Percutaneous transluminal coronary angioplasty vs Medical therapy, bypass surgery, or thrombolytic…
Design
Review
Authors
Loading...
Supports PTCA in select CAD presentations; leaves open updated comparisons with contemporary stents and medical therapy.
Does percutaneous transluminal coronary angioplasty (PTCA) improve clinical outcomes across different presentations of coronary artery disease compared to medical therapy, bypass surgery, or thrombolysis?
PTCA plays a critical and evolving role in managing coronary artery disease, with specific benefits and limitations depending on the clinical presentation.
Paul T. Vaitkus (1995) conducted a review in Coronary artery disease. Percutaneous transluminal coronary angioplasty (PTCA) vs. Medical therapy, bypass surgery, or thrombolytic therapy was evaluated. PTCA alleviates symptoms in stable angina, has similar mortality to bypass surgery in multivessel disease, and reduces recurrent ischemic events compared to thrombolysis in acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: